Immunotherapy after surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that could be removed with surgery (stage II to IIIB).
- You received 3 to 4 cycles of immunotherapy combined with chemotherapy before surgery.
- After surgery, tests showed that less than 10% of the original tumor was still present (called a major pathological response).
- Your surgery completely removed the cancer with clear margins, and you had proper lymph node removal.
- You are in good overall health (able to do daily activities) and have no serious side effects from the prior treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests whether giving an experimental drug (SYS6010) together with an immunotherapy (a type of treatment that helps your immune system fight cancer) after surgery can lower the chance of cancer coming back. It's for people with non-small cell lung cancer that was completely removed but didn't respond very well to surgery alone.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.